| Identification | Back Directory | [Name]
Pioglitazone | [CAS]
105355-27-9 | [Synonyms]
Pioglitazone
5-[[4-[2-(5-Ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}Methyl)-1,3-thiazolidine-2,4-dione hydrochloride | [Molecular Formula]
C19H20N2O3S | [MOL File]
105355-27-9.mol | [Molecular Weight]
356.44 |
| Hazard Information | Back Directory | [Definition]
ChEBI: Pioglitazone is a member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. It has a role as an insulin-sensitizing drug, an EC 2.7.1.33 (pantothenate kinase) inhibitor, a xenobiotic, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor, a ferroptosis inhibitor, a cardioprotective agent, a PPARgamma agonist, an antidepressant, a geroprotector and a hypoglycemic agent. It is a member of thiazolidinediones, an aromatic ether and a member of pyridines. | [Clinical Use]
Treatment of type 2 diabetes mellitus | [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
Pioglitazone undergoes extensive hepatic metabolism
by hydroxylation mainly via cytochrome P450 2C8
to form active and inactive metabolites. Three of the
six identified metabolites are active (M-II, M-III, and
M-IV). Following oral administration of radiolabelled
pioglitazone to man, recovered label was mainly in faeces
(55%) and a lesser amount in urine (45%). |
|
| Company Name: |
J S LABS
|
| Tel: |
+91-7330612784 +91-7330612784 |
| Website: |
www.jslaboratories.com |
| Company Name: |
NovoChemy Ltd.
|
| Tel: |
021-31261262/ 49 (0)17662837245 |
| Website: |
www.novochemy.com |
|